The 5 Questions Every Cancer Patient Must Ask to Avoid the Wrong Treatment

This video discusses the critical issue of cancer treatment heterogeneity, where the same cancer type and stage can present with different markers. This often leads to patients receiving ineffective medications, highlighting a crisis in cancer therapy. Deeper analysis, using advanced techniques like next generation sequencing, could identify the correct targeted therapy and improve patient outcomes. Understanding what is cancer at the genetic level is crucial for effective care.🎯 What You’ll Learn in This Episode• Why cancer treatment may not be one-size-fits-all• What tumor heterogeneity means• The role of DNA and RNA testing• Why immune system considerations matter• How treatment decisions are made• What questions to ask your oncologist• Why deeper data may influence care• How personalized approaches are evolving📍 Envita Medical Centers – Scottsdale, AZ🌐 Learn more: www.envita.com📞 Speak with a care coordinator: 866-830-4576“The right questions can help you better understand your treatment options.”Disclaimer This podcast is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your licensed healthcare provider before making any medical decisions. Individual results will vary, and Envita Medical Centers does not guarantee outcomes. Some treatments discussed may not be FDA-approved or available in all locations. Testimonials are shared with patient consent and may not reflect typical results. Do not delay or disregard professional medical care based on the podcast's content. Certain treatments may be available only at Envita’s international clinic in Hermosillo, Mexico. No specific outcomes are promised or implied.________________________________________Outcomes DisclaimerThe results referenced from Envita's Precision Cancer Care: 35-Fold Improvement in Response Rates are from a retrospective analysis of 199 late-stage cancer patients treated at Envita Medical Centers between 2021 and 2023, as published in the Journal of Cancer Therapy. These outcomes are not guaranteed and will vary based on individual factors such as cancer type, stage, genetics, immunity and prior treatments. Any comparisons to standard care or clinical trials are based on published data and internal analysis, not head-to-head studies. Individual results will vary.You can read the full peer-reviewed study at: https://www.scirp.org/journal/paperinformation?paperid=132493